A mix of tolerable benefit cuts and realistic revenue increases would make everyone better off In early January, Stephen Goss, Social Security's chief actuary released estimates of a comprehensive ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Discover how tirzepatide, a diabetes drug, offers hope for congenital generalized lipodystrophy (CGL) treatment, potentially ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

A weekly injection of diabetes medication could replace painful daily hormone shots for patients with a rare form of lipodystrophy.

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

GLP-1 injections, such as semaglutide and tirzepatide products like Ozempic, Wegovy, Mounjaro and Zepbound have led many consumers to spend significantly less money on food — both at grocery stores ...